TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21865044

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 244

Group type: COMPARATOR
Intervention: External breast radiotherapy (EBRT)
Number of subjects: 244
Study: 20814326

Group type: EXPERIMENTAL
Intervention: Scores rated by the physician in charge (PIC) using the Positive and Negative Syndrome Scale (PANSS).
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scores rated by non-PIC psychiatrists using the PANSS.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scores rated by one of the non-PIC physicians using the PANSS.
Number of subjects: 36
Study: 17932848

Group type: EXPERIMENTAL
Intervention: Chloramphenicol 0.25%-betamethasone 0.13% gel three times a day (Group 1)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tobramycin 0.3%-dexamethasone 0.1% eyedrops four times a day (Group 2)
Number of subjects: 142
Study: 16249353

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m² i.v. day 1) and topotecan (1.5 mg/m² i.v. days 1, 2, and 3) every 21 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m² i.v. day 1), carboplatin (AUC 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1-10) every 21 days
Number of subjects: 120
Study: 12032162

Group type: EXPERIMENTAL
Intervention: Corn oil (CO) diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olive/sunflower oil (O/SO) diet
Number of subjects: 26
Study: 9952060

Group type: EXPERIMENTAL
Intervention: 0.30 g/kg ethanol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.60 g/kg ethanol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7799016

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 399
Study: 2316795

Group type: EXPERIMENTAL
Intervention: Government Pharmaceutical Organization of Thailand antivenom (mostly F(ab)2 fragments)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Twyford antivenom of caprine origin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thai Red Cross antivenom
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All antivenoms
Number of subjects: 26
Study: 396687

Group type: EXPERIMENTAL
Intervention: Inhaled clemastine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30407031

Group type: EXPERIMENTAL
Intervention: Challenging gait and balance training (including single and dual-task conditions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 100
Study: 27539604

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study: 25711322

Group type: EXPERIMENTAL
Intervention: HIV RNA <50 copies/mL
Number of subjects: 4676

Group type: EXPERIMENTAL
Intervention: HIV RNA between 51 and 400 copies/mL
Number of subjects: 4676

Group type: EXPERIMENTAL
Intervention: Factors associated with low HIV RNA
Number of subjects: 4676

Group type: EXPERIMENTAL
Intervention: HCV antibody positivity
Number of subjects: 4676

Group type: EXPERIMENTAL
Intervention: Race and HBV surface antigen positivity
Number of subjects: 4676
Study: 23372725

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21320361

Group type: EXPERIMENTAL
Intervention: Self-practice/self-reflection workbook
Number of subjects: 16
Study: 19726820

Group type: EXPERIMENTAL
Intervention: Early discharge 2 hours following successful PCI with adjunctive bivalirudin therapy and a femoral arterial closure device
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine care with an overnight hospital stay
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 39
Study: 17349088

Group type: EXPERIMENTAL
Intervention: n-3-enriched foods (EPA + DHA intake of 1 g/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 86
Study: 15078017

Group type: EXPERIMENTAL
Intervention: Custom-made soft contact lenses (SCLs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standard soft contact lenses (SCLs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aberration-free soft contact lenses (SCLs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Best-correcting spectacle lens
Number of subjects: 23
Study: 11729012

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 96
Study: 9397098

Group type: EXPERIMENTAL
Intervention: 100 micrograms of misoprostol at 6‐hour intervals (n = 27)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol at 12‐hour intervals (n = 26)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 1.0 mg of gemeprost at 3‐hour intervals (n = 28)
Number of subjects: 81
Study: 8359080

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 3307842

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (45 Gy)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Postoperative irradiation (45 Gy)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 519
Study: 30215301

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 31215685

Group type: EXPERIMENTAL
Intervention: Optimal Bayesian adaptive (OBA) design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal randomization (ER) design
Number of subjects: 0
Study: 28077223

Group type: EXPERIMENTAL
Intervention: Lifestyle advice
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lifestyle advice and tandem skydive
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 25686344

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Restraint
Number of subjects: 62
Study: 24001698

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8863

Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8863
Study: 21993867

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 39
Study: 19593713

Group type: EXPERIMENTAL
Intervention: Forewarning about congestion
Number of subjects: 49

Group type: COMPARATOR
Intervention: No warning about congestion
Number of subjects: 49
Study: 16846498

Group type: EXPERIMENTAL
Intervention: Red palm oil (RPO) added to school meals (15 ml, 3 times a week)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Vitamin A capsule (60 mg) given at the end of the school year
Number of subjects: 239

Group type: COMPARATOR
Intervention: Red palm oil (RPO) through the school year
Number of subjects: 239
Study: 14656784

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micro g, lockout six‐minute
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micro g, lockout three‐minute
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 micro g, lockout three‐minute
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 60
Study: 10857368

Group type: EXPERIMENTAL
Intervention: Laser light exposure
Number of subjects: 83

Group type: COMPARATOR
Intervention: Broadband lamp (BL) light exposure
Number of subjects: 83
Study: 9182132

Group type: EXPERIMENTAL
Intervention: Polymorphonuclear granulocytes count in blood
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Streptococci showing antagonistic activity
Number of subjects: 92
Study: 1399944

Group type: EXPERIMENTAL
Intervention: RP 59500 (1.4, 2.8, 4.6, 7.0, 9.8, 12.6, 16.8, 22.4, 29.4 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6235453

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B), 40 micrograms each, administered in three doses.
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 1311

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Heptavax‐B).
Number of subjects: 1311
Study: 31049735

Group type: EXPERIMENTAL
Intervention: Dietary exposure biomarker discovery and validation strategy based on a food intervention study
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Different food formulations and processing methods involving meat, wholegrain, fruits and vegetables
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spot urine samples with robust dietary biomarkers
Number of subjects: 51
Study: 29767688

Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study: 26170158

Group type: EXPERIMENTAL
Intervention: Laparoscopy-Assisted Distal Gastrectomy (LADG) with D2 lymph node dissection
Number of subjects: 180

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 180
Study: 23951281

Group type: EXPERIMENTAL
Intervention: Post-isometric relaxation (PIR)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Static stretch combined with stabilizing exercises (SS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stabilizing exercises (SE)
Number of subjects: 120
Study: 20385664

Group type: EXPERIMENTAL
Intervention: Neutral stimuli
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Negative pictures
Number of subjects: 159
Study: 19410073

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine (Lido group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3% Prilocaine with 1:200000 felypressin (Prilo group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4% Prilocaine without vasoconstrictor (Prilo‐no‐VC group)
Number of subjects: 30
Study: 17298657

Group type: EXPERIMENTAL
Intervention: Rapid smoking (RS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (health promotion video)
Number of subjects: 100
Study: 19780244

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with modern two-drug platinum-based combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemotherapy with alkylating agent-based therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 0
Study: 11316508

Group type: EXPERIMENTAL
Intervention: Homeopathic belladonna 30CH
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 87
Study: 8195454

Group type: EXPERIMENTAL
Intervention: Flutamide (nonsteroidal androgen receptor blocking agent)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 2884455

Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccine (RIT 4237), 3 doses administered concurrently with oral or killed polio vaccine.
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo/oral polio group (unvaccinated control).
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Rotavirus/oral polio group.
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo/oral polio group.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Rotavirus/killed polio group.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Overall vaccine efficacy of RIT 4237.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: RIT 4237.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Concurrent administration of oral polio vaccine with rotavirus vaccine.
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Oral polio and rotavirus vaccines.
Number of subjects: 276
Study: 28905683

Group type: EXPERIMENTAL
Intervention: Modified walk-in system
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Scheduled appointment
Number of subjects: 1286
Study: 28800001

Group type: EXPERIMENTAL
Intervention: Electrical cardiometry (SVEC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound (SVUS)
Number of subjects: 30
Study: 26344094

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 24125672

Group type: EXPERIMENTAL
Intervention: 250 mAs (conventional dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mAs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 150 mAs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 mAs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 80 mAs
Number of subjects: 100
Study: 21309444

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (reducing 21‐30 Hz activity and increasing 10 Hz activity, 5 sessions for each affected site)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Drug therapy (control group)
Number of subjects: 71
Study: 18342111

Group type: EXPERIMENTAL
Intervention: Avène thermal spring water anti burning gel (ATSW gel)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Trolamine cream (Control)
Number of subjects: 69
Study: 16797393

Group type: EXPERIMENTAL
Intervention: iPTH/80
Number of subjects: 43

Group type: COMPARATOR
Intervention: iPTH/120
Number of subjects: 43
Study: 12890465

Group type: EXPERIMENTAL
Intervention: Adhesive retention tape Mefix
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alginate Kaltostat
Number of subjects: 50
Study: 10966908

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+; 80.4 mg/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein (SPI-)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Whey protein (control)
Number of subjects: 69
Study: 9120512

Group type: EXPERIMENTAL
Intervention: Electrophysiologic study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 0
Study: 8342427

Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Number of subjects: 56

Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 56
Study: 3553280

Group type: EXPERIMENTAL
Intervention: Double‐blind placebo‐controlled food challenges
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Instructional diet sheets based on identification of 'key words' on food labels
Number of subjects: 120
Study: 29610960

Group type: EXPERIMENTAL
Intervention: CI522
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CI512
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CI532
Number of subjects: 21
Study: 27355447

Group type: EXPERIMENTAL
Intervention: Advanced cook-stove intervention
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Electronic data capture using eCRFs on mobile technology
Number of subjects: 664
Study: 25033582

Group type: EXPERIMENTAL
Intervention: IOP reduction measured with Dynamic Contour tonometer (DCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IOP reduction measured with Goldmann Applanation tonometer (GAT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude (OPA) measured using DCT
Number of subjects: 60
Study: 23370288

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 21114406

Group type: EXPERIMENTAL
Intervention: Lukewarm saline and yoga postures (LWS/yoga)
Number of subjects: 54

Group type: COMPARATOR
Intervention: NuLytely(®) (PEG‐3350, sodium chloride, sodium bicarbonate, and potassium chloride solution)
Number of subjects: 54
Study: 17689667

Group type: EXPERIMENTAL
Intervention: Internet-administered Edinburgh Depression Scale (EDS)
Number of subjects: 407
Study: 15731595

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Non-BIS control
Number of subjects: 1580
Study: 12515739

Group type: COMPARATOR
Intervention: Atorvastatin 0 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Troleandomycin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 44
Study: 10773774

Group type: EXPERIMENTAL
Intervention: Weekly group psychotherapy for 4 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two educational sessions over a period of 1 month
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 20
Study: 8862532

Group type: EXPERIMENTAL
Intervention: Moderate fat enteral formula (41% fat calories)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High fat enteral formula (55% fat calories)
Number of subjects: 36
Study: 8482178

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg per os three times a day before meals)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 38
Study: 4028283

Group type: EXPERIMENTAL
Intervention: cephemic cofosfolactamine
Number of subjects: 127

Group type: COMPARATOR
Intervention: cephalexin
Number of subjects: 127

Group type: COMPARATOR
Intervention: fosfomycin
Number of subjects: 127
Study: 31653795

Group type: EXPERIMENTAL
Intervention: Accuro (ultrasound device)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control (palpation-guided spinal anesthesia)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Accuro
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study: 29803904

Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (after switching from other treatments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or etanercept)
Number of subjects: 0
Study: 25726428

Group type: EXPERIMENTAL
Intervention: Resistance exercise program + 10 g/day BCAA supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resistance exercise program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall sample (both groups)
Number of subjects: 0
Study: 25369174

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extract, 1g KRG extract/pouch, twice a day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) extract
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23135095

Group type: EXPERIMENTAL
Intervention: Sorafenib (SO) or Sunitinib (SU)
Number of subjects: 23
Study: 19907160

Group type: EXPERIMENTAL
Intervention: Amlodipine (usual MAP goal)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amlodipine (lower MAP goal)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CYP3A5 A6986G
Number of subjects: 164
Study: 18565338

Group type: EXPERIMENTAL
Intervention: Excision with primary closure and drainage (group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Excision with primary closure without drainage (group B)
Number of subjects: 103
Study: 15756351

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Core Needle Biopsy (CNB)
Number of subjects: 296
Study: 12703665

Group type: EXPERIMENTAL
Intervention: Standard HIV prevention protocol
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Enhanced HIV prevention protocol
Number of subjects: 1728
Study: 10485773

Group type: EXPERIMENTAL
Intervention: Imaging stylet intubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy
Number of subjects: 0
Study: 9139276

Group type: EXPERIMENTAL
Intervention: Patients after biliary acute pancreatitis (AP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (ChP) with normal carbohydrate tolerance
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis and impaired glucose tolerance (ChP + IGT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study: 1931065

Group type: EXPERIMENTAL
Intervention: Thiopental sodium 1.5 mg/kg IV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg IV
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention for 3.5 minutes)
Number of subjects: 30
Study: 6849167

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31226435

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (3 g of starch)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High intensity physical training (Deep Water Running for 8 weeks, 3 times/week, 50 min/session at 70-85% maximum heart rate)
Number of subjects: 22
Study: 30314452

Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years
Number of subjects: 30848

Group type: EXPERIMENTAL
Intervention: TAM 5y - AI 5y treatment
Number of subjects: 30848

Group type: EXPERIMENTAL
Intervention: (AI and/or TAM) 5y - LET 5y treatment
Number of subjects: 30848

Group type: COMPARATOR
Intervention: TAM 5y - TAM 5y treatment
Number of subjects: 30848

Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in lymph node-positive subgroup
Number of subjects: 30848

Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in postmenopausal subgroup
Number of subjects: 30848

Group type: EXPERIMENTAL
Intervention: Extended endocrine therapy to 10 years in ER+ and/or PR+ subgroup
Number of subjects: 30848
Study: 25831994

Group type: EXPERIMENTAL
Intervention: Traditional gender role attitudes at T1
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Injunctive norms and gender role attitudes
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Simultaneously targeting injunctive norms and gender role attitudes
Number of subjects: 577
Study: 25260948

Group type: EXPERIMENTAL
Intervention: Septal myectomy
Number of subjects: 25